/PRNewswire/ The "Blood Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com s offering This report provides strategists,.
Swedish Orphan Biovitrum is acquiring CTI Biopharma in a $1.7 billion deal centered on the biotech’s commercialized drug for the blood cancer myelofibrosis. Sobi says the drug, Vonjo, complements one of its own assets approved for a different blood disorder.
HBM Healthcare Investments AG / Key word: Personnel
HBM Healthcare Investments year-end results 2022/2023
12-May-2023 / 06:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53. | May 12, 2023
On a call discussing first quarter results, chief exec Emma Walmsley (pictured) said the firm had more in the hopper as it scoped out new takeover targets.